Hideo Gobara1, Yasuaki Arai2, Takeshi Kobayashi3, Koichiro Yamakado4, Yoshitaka Inaba5, Yoshihisa Kodama6, Takuji Yamagami7, Miyuki Sone8, Hirokazu Watanabe2, Yoshihiro Okumura9, Takayoshi Shinya10, Hiroaki Kurihara2, Susumu Kanazawa10. 1. Department of Radiology, Okayama University Medical School, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Japan. gobara@cc.okayama-u.ac.jp. 2. Department of Diagnostic Radiology, National Cancer Center, Tokyo, Japan. 3. Department of Interventional Radiology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan. 4. Department of Interventional Radiology, Mie University School of Medicine, Tsu, Japan. 5. Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan. 6. Department of Radiology, Teine Keijinkai Hospital, Sapporo, Japan. 7. Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. 8. Department of Radiology, Iwate Medical University School of Medicine, Morioka, Japan. 9. Department of Radiology, Fukuyama City Hospital, Fukuyama, Japan. 10. Department of Radiology, Okayama University Medical School, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Japan.
Abstract
PURPOSE: This prospective multicenter study aimed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for lung cancer. MATERIALS AND METHODS: From May 2008 to April 2012, 33 patients (26 men, 7 women; mean age 70.5 years) were enrolled. RF ablation was performed using an internally cooled or expandable multitined electrode. The primary endpoint was complete response (CR) determined using (18)F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed 6 months after RF ablation. The secondary endpoint was the incidence and grade of adverse events (AEs) evaluated using the Common Toxicity Criteria for Adverse Events, version 3.0. RESULTS: All patients underwent RF ablation and had efficacy analyses evaluated; however, FDG-PET/CT images before RF ablation were not available for two patients. The CR rate was 68 % (21 of 31 patients). One patient had a grade 5 AE unrelated to RF ablation. Grade ≥3 AEs occurred in 12 % of patients. During the follow-up period (median 37 months; range 1-55 months), five patients developed local tumor progression and nine (29 %) died. Overall survival at 1, 2, and 3 years was 97, 82, and 74 %, respectively. CONCLUSION: Percutaneous RF ablation is a safe, feasible, and effective treatment for small malignant lung tumors.
PURPOSE: This prospective multicenter study aimed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for lung cancer. MATERIALS AND METHODS: From May 2008 to April 2012, 33 patients (26 men, 7 women; mean age 70.5 years) were enrolled. RF ablation was performed using an internally cooled or expandable multitined electrode. The primary endpoint was complete response (CR) determined using (18)F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed 6 months after RF ablation. The secondary endpoint was the incidence and grade of adverse events (AEs) evaluated using the Common Toxicity Criteria for Adverse Events, version 3.0. RESULTS: All patients underwent RF ablation and had efficacy analyses evaluated; however, FDG-PET/CT images before RF ablation were not available for two patients. The CR rate was 68 % (21 of 31 patients). One patient had a grade 5 AE unrelated to RF ablation. Grade ≥3 AEs occurred in 12 % of patients. During the follow-up period (median 37 months; range 1-55 months), five patients developed local tumor progression and nine (29 %) died. Overall survival at 1, 2, and 3 years was 97, 82, and 74 %, respectively. CONCLUSION: Percutaneous RF ablation is a safe, feasible, and effective treatment for small malignant lung tumors.
Authors: Damian E Dupuy; Hiran C Fernando; Shauna Hillman; Thomas Ng; Angelina D Tan; Amita Sharma; William S Rilling; Kelvin Hong; Joe B Putnam Journal: Cancer Date: 2015-06-19 Impact factor: 6.860